Composition
Tab 200 mg/300 mg/400 mg: Dexibuprofen 200 mg/300 mg/400 mg; Susp: Per 5 ml: Dexibuprofen 100 mg.
Indications & Dosage
Pain and inflammation associated with osteoarthritis and other musculoskeletal disorders, pain and inflammation including dental pain: Adult: 600-900 mg daily in up to 3 divided doses; increased if necessary up to 1.2 g daily (max. per dose 400 mg). Pain and inflammation in dysmenorrhea: Adult: 600-900 mg daily in up to 3 divided doses (max. per dose 300 mg); max. 900 mg per day.
Contraindications
Active or recurrent GI bleeding or ulceration, cerebrovascular disease, history of GI bleeding or GI perforation related to previous NSAID therapy, history of recurrent GI haemorrhage, ischaemic heart disease, heart failure, peripheral arterial disease, moderate to severe renal impairment, aspirin/anti-inflammatory induced allergy.
Precautions
Renal, hepatic or cardiac impairment. GI disease, allergic disorders, avoid in acute porphyrias, coagulation defects, connective-tissue disorders, Crohns disease (may be exacerbated), elderly, oedema, risk factors for cardiovascular events, ulcerative colitis (may be exacerbated)
Interactions
Anticoagulants, diuretics, quinolones, antihyper-tensives, ACE inhibitors, cardiac glycosides, lithium, methotrexate, cyclosporin, tacrolimus, mifepristone, other NSAIDs, corticosteroids, phenytoin, sulfonylureas, probenecid, sulfinpyrazone, ticlopidine, zidovudine.
Pregnancy
Contraindicated in pregnancy.
Lactation
Contraindicated or not recommended.
Side Effects
Angioedema, blood disorders, bronchospasm, colitis, Crohns disease, depression, diarrhoea, dizziness, drowsiness, fluid retention, GI bleeding and ulceration, GI disturbances, haematuria, headache, hearing disturbances, hypersensitivity reactions, insomnia, nausea, nervousness, photosensitivity, raised blood pressure, rashes, renal failure (especially in patients with preexisting renal impairment), tinnitus, vertigo. Rare: hepatic damage, interstitial fibrosis associated with NSAIDs, Stevens-Johnson syndrome, toxic epidermal necrolysis, visual disturbances